2024-02-23T11:45:25-06:00 2023-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2022-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC LEUK 9149495213 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 GORDON MILLER JR EVP CHIEF FINANCIAL OFFICER 9149495213 2024-02-23 1 GORDON MILLER JR 999009999 0 DEVIN L DUNCAN P01249521 2127589700 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z E ANDERS KOLB MD 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 640723525 0 X WWW.LLS.ORG X 1949 NY CURE LEUKEMIA,LYMPHOMA,HODGKIN'S DISEASE, MYELOMA; IMPROVE QUALITY OF LIFE OF PATIENTS AND FAMILIES. 17 17 1181 3000000 0 0 400540019 357670634 11597762 9531279 6919696 15134480 7939727 -3997903 426997204 378338490 299213836 147771106 0 0 112055516 119899883 5554287 4917672 50579954 101798755 113484307 518622394 386072968 -91625190 -7734478 693676206 643891871 321732744 271338303 371943462 372553568 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 0 0 104409883 55409990 9531279 A) RESEARCH PROGRAMS:AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 70 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS.AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2023, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE.TO DATE, LLS HAS INVESTED OVER $1.7 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO A 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS.IN FISCAL YEAR 2023, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY $61.96 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS.IMPACT RESEARCH GRANTSTO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN 2021 WE ACTIVATED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF $3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022.THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS.THERAPY ACCELERATION PROGRAM (TAP)TAP IS LLS' MISSION-DRIVEN, STRATEGIC VENTURE PHILANTHROPY INITIATIVE THAT SEEKS TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE BLOOD CANCER THERAPEUTICS AND CHANGE THE STANDARD OF CARE, WHILE ALSO GENERATING A RETURN ON INVESTMENT FOR THE LLS MISSION. TAP COLLABORATES WITH BIOTECH COMPANIES TO SUPPORT THE DEVELOPMENT OF NOVEL PLATFORMS, FIRST-IN-CLASS ASSETS ADDRESSING UNMET MEDICAL NEEDS, EMERGING PATIENT POPULATIONS AND EVEN RARE BLOOD CANCERS.ESTABLISHED IN 2007, TAP HAS INVESTED MORE THAN $140 MILLION IN OVER 70 PROJECTS. SINCE 2017, FOUR TAP-SUPPORTED THERAPIES HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OR INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES. CURRENTLY, THERE ARE OVER 20 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING SEVERAL REGISTRATION-ENABLING CLINICAL STUDIES IN BLOOD CANCER THAT COULD LEAD TO MORE FDA APPROVALS.BETWEEN JULY 2022 JUNE 2023 (FY23), TAP MADE INVESTMENTS IN SEVEN BIOTECH COMPANIES THAT INCLUDED THREE EXISTING BIOTECH PARTNERS AND FOUR BRAND NEW UP-AND-COMING BIOTECH COMPANIES, TO HELP THEM NAVIGATE THE DRUG DEVELOPMENT LANDSCAPE AND TO SUPPORT CLINICAL TRIALS FOR BLOOD CANCER PATIENTS. SEVERAL OF THESE COMPANIES ARE BASED IN EUROPE AND NOW, WITH HELP FROM TAP, THESE COMPANIES ARE RUNNING CLINICAL TRIALS IN THE US.NATIONAL PATIENT REGISTRY COVID INFORMATIONTHE COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 9,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS."THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY (INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION.CLINICAL TRIALSBEAT AML MASTER TRIALBEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION.ADVANCING HEALTH EQUITYTO OVERCOME DISPARITIES IN HEALTH CARE, WE MUST UNDERSTAND THE OBSTACLES. IN 2022, WE LAUNCHED THIS SIGNATURE PROGRAM AS PART OF OUR LONGSTANDING EFFORT TO UNDERSTAND BARRIERS IN BLOOD CANCER TREATMENT AND IDENTIFY SOLUTIONS TO IMPROVE ACCESS TO CARE. WE GRANTED OVER $4.7 MILLION IN COMBINED FUNDING FOR THREE TEAMS OF PREEMINENT RESEARCHERS, CHARGED WITH UNCOVERING THE ROOT CAUSES OF HEALTH DISPARITIESINFORMATION WE CAN USE TO URGE LAWMAKERS AND HEALTHCARE PRACTITIONERS TO AFFECT POSITIVE CHANGE. 141014110 92361116 B) PATIENT & COMMUNITY SERVICES:AN ESTIMATED 1.6 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS.FINANCIAL ASSISTANCEOUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, LLS PROVIDED MORE THAN 69,100 GRANTS TOTALING OVER $246M IN ASSISTANCE AWARDED. THE LION'S SHARE-OVER $229 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM.IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN FY23, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 86% OF ALL U.S. COUNTIES AND 82% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES.CO-PAY ASSISTANCE PROGRAMTHE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS.PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2023, LLS AWARDED 22,220 GRANTS THROUGH ITS CO-PAY ASSISTANCE PROGRAM.SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAMLLS AWARDED OVER 5,060 GRANTS EACH IN THE AMOUNT OF $2,500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL.SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAMLLS AWARDED OVER 8,040 GRANTS EACH IN THE AMOUNT OF $500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS.URGENT NEED PROGRAMIN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS AWARDED OVER 16,740 GRANTS EACH IN THE AMOUNT OF $500 FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD.LOCAL FINANCIAL ASSISTANCE PROGRAM LLS AWARDED OVER 2,410 GRANTS EACH IN THE AMOUNT OF $500 TO COVER NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD, ETC. FINANCIAL RELIEF FUND LLS AWARDED ONE-TIME STIPENDS OF $250 TO OVER 930 PATIENTS WHO RESIDED IN DESIGNATED ZIP CODES DECLARED FOR INDIVIDUAL ASSISTANCE BY FEMA, IN FLORIDA AND PUERTO RICO TO ALLEVIATE FINANCIAL HARDSHIP AS A RESULT OF THE HURRICANES. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF $100 TO OVER 18,640 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORSIN 2023, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS AWARDED 176 SCHOLARSHIPS EACH UP TO $7,500 IN TUITION SUPPORT FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION. 19597702 C) PUBLIC HEALTH EDUCATION:LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER.ONE-ON-ONE EDUCATION AND SUPPORTTRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) PROVIDE PATIENTS AND CAREGIVERS WITH COMPASSIONATE, COMPREHENSIVE, AND TAILORED DISEASE AND TREATMENT INFORMATION, INCLUDING REFERRALS AND LINKS TO APPROPRIATE EDUCATIONAL RESOURCES AND LITERATURE; PSYCHOSOCIAL SUPPORT INFORMATION FOR ANY POINT IN THEIR TREATMENT JOURNEY; REFERRALS TO RELEVANT LOCAL, STATE AND/OR NATIONAL RESOURCES FOR ASSISTANCE; COVID-19 RELATED INFORMATION AND GUIDANCE; AND FINANCIAL RESOURCE INFORMATION TO COVER COSTS OF TREATMENT, TRAVEL, URGENT NEEDS AND MORE. OVER 25,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE LAST YEAR.FACILITATING CLINICAL TRIAL ACCESSTHE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,345 PATIENTS (AN INCREASE OF 34% OVER 2022). TWENTY THREE PERCENT OF THESE PATIENTS ENTERED A TRIAL.OUTREACH TO UNDERSERVED GROUPSWE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL STAFF AND VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS.MOREOVER, WE EXPANDED PARTNERSHIPS WITH ADDITIONAL AFFINITY GROUPS INCLUDING: THE BALM IN GILEAD, NCI'S NATIONAL OUTREACH NETWORK, MIGRANT CLINICIANS NETWORK, AND THE MEDICAL ORGANIZATION FOR LATINO ADVANCEMENT.THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2023, LLS REACHED OVER 60,000 PEOPLE THROUGH APPROXIMATELY 50 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 16 CITIES.IN 2023, THE LLS LATINO OUTREACH PILOT REACHED OVER 115,000 SPANISH-SPEAKING COMMUNITY MEMBERS THROUGH COMMUNITY PROGRAMS ACROSS 7 MAJOR HISPANIC MARKETS (INCLUDING PR) AND OUR PARTNERSHIP WITH ENTRAVISION AND PRIME TIME INTERVIEWS WITH BOTH UNIVISION AND TELEMUNDO. EDUCATION AND PATIENT CONNECTIONSOUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS.LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 950 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIANS.OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 1,900 PATIENTS WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE.IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 20,852, AN INCREASE OF 9% OVER FISCAL YEAR 2022. 12095021 D) PROFESSIONAL EDUCATION:LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL DEPARTMENT OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2023:-LLS PROVIDED 21 (INCLUDING 2 MULTI SESSION SERIES) CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 2801 HEALTHCARE PROFESSIONALS IN ATTENDANCE.- OVER 21,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY.--THERE WERE OVER 300,000 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, VIRTUAL LECTURES AND VIDEOS AND OVER 128,000 PODCAST DOWNLOADS. NEARLY 725,000 BOOKLETS AND FACT SHEETS WERE EITHER DOWNLOADED OR ORDERED IN HARD COPY. 12095021 277116716 1 1 0 1 0 0 0 1 0 1 1 0 0 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 364 0 1 1181 1 0 1 CA 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 X JEFF SACHS CHAIR 4.00 0.00 X X 0 0 0 KATHLEEN MERIWETHER VICE CHAIR 4.00 0.00 X X 0 0 0 FREDA WANG SECRETARY/TREASURER 4.00 0.00 X X 0 0 0 RUBEN MESA FACP MD AT LARGE 4.00 0.00 X X 0 0 0 RICHARD BAGGER BOD MEMBER 4.00 0.00 X 0 0 0 MICHELE CAMERON - END 121522 BOD MEMBER 4.00 0.00 X 0 0 0 RENZO CANETTA MD BOD MEMBER 4.00 0.00 X 0 0 0 CASEY CUNNINGHAM MD BOD MEMBER 4.00 0.00 X 0 0 0 JANICE GABRILOVE MD BOD MEMBER 4.00 0.00 X 0 0 0 JOHN GREENE BOD MEMBER 4.00 0.00 X 0 0 0 FRANCINE HELLER BOD MEMBER 4.00 0.00 X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 0.00 X 0 0 0 MARLA PERSKY BOD MEMBER 4.00 0.00 X 0 0 0 JIM REDDOCH BOD MEMBER 4.00 0.00 X 0 0 0 RICHARD RENDINA BOD MEMBER 4.00 0.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 0.00 X 0 0 0 BART SICHEL BOD MEMBER 4.00 0.00 X 0 0 0 ALESSANDRA TOCCO BOD MEMBER 4.00 0.00 X 0 0 0 LOUIS JDEGENNARO-END 63023 PRESIDENT & CEO 40.00 1.00 X 879546 0 51863 E ANDERS KOLB - START 512023 PRESIDENT & CEO 40.00 1.00 X 0 0 0 GWEN NICHOLS EVP, CHIEF MEDICAL OFFICER 40.00 0.00 X 552575 0 48137 TROY DUNMIRE EVP, CHIEF OPERATING OFFICER 40.00 0.00 X 537877 0 53774 DALE NISSENBAUM EVP, GENERAL COUNSEL 40.00 0.00 X 504418 0 39434 GORDON MILLER JR EVP, CHIEF FINANCIAL OFFICER 40.00 1.00 X 449353 0 55128 COKER POWELL SVP, CHIEF DEVELOPMENT OFFICER 40.00 0.00 X 440143 0 25520 VANESSA WHITE SVP, CHIEF ADVANCEMENT OFFICER 40.00 0.00 X 431334 0 30306 SUSAN BROWN SVP, CHIEF DEI OFFICER 40.00 0.00 X 425506 0 45929 LEE GREENBERGER SVP, CHIEF SCIENTIFIC OFFICER 40.00 0.00 X 401142 0 43331 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFFICER 40.00 0.00 X 381803 0 42096 5003697 0 435518 280 0 1 0 PATIENT ADVOCATE FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 9386412 ICON PLC - PHARMACEUTICAL RESEARCH ASSOC 4130 PARKLAKE AVENUE SUITE 400 RALEIGH NC 27612 CLINICAL TRIAL 5098790 RESOURCE ONE COMMUNICATIONS 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETING 4897034 META PLATFORMS 1 HACKER WAY MENLO PARK CA 94025 ADVERTISING 4468458 SALESFORCE 140 E 45TH ST NEW YORK NY 10017 SOFTWARE 4046730 167 317204 144824080 212529350 2410703 357670634 SERVICE REVENUE 810000 9531279 9531279 9531279 11201769 11201769 1864647 1864647 243457848 239525137 3932711 3932711 3932711 16964118 144824080 22854323 -5890205 -5890205 33230 5575 27655 27655 378338490 9531279 0 11136577 47337227 47337227 92361116 92361116 8072763 8072763 2682939 1061429 1127386 494124 93026618 47637080 24804672 20584866 3247539 1560427 992969 694143 14299798 6897106 4334320 3068372 6642989 3191923 2031164 1419902 1494234 896541 403443 194250 519205 519205 3445639 3445639 4917672 4917672 216836 159794 29540 27502 35980021 25536784 6087072 4356165 9534205 5219449 1403758 2910998 14901859 7832923 2023194 5045742 12947167 976216 9617156 2353795 5356295 2647657 1362525 1346113 8204269 5542948 1383997 1277324 4699950 2660109 1181954 857887 1459206 847284 341469 270453 RESEARCH & DEVELOPMENT 11908214 11908214 MISCELLANEOUS 2817207 1324087 732474 760646 386072968 277116716 58376298 50579954 X 18113659 10544026 0 7569633 10533722 1093408 59563249 87996059 24346058 29923480 5700688 5045849 29353185 16102001 10534101 13251184 560279919 463285795 20361812 20291527 2356657 10015427 516667 12472475 693676206 643891871 29802071 21647040 278233023 219704797 13697650 15561185 0 14425281 321732744 271338303 X 301387942 281881454 70555520 90672114 371943462 372553568 693676206 643891871 X -7734478 8559897 -215313 X 0 1 X 1 0 X 372750094 427419530 441317494 400540019 357670634 1999697771 372750094 427419530 441317494 400540019 357670634 1999697771 559584094 1440113677 11830162 29082073 16877123 18087763 13066416 88943537 2088641308 75634768 0.68950 0.70010 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 1 26813 0 1 62160 0 1 374184 1 725202 1 2257280 3445639 0 PART II-B, LINE 1: LLS PARTICIPATES IN A NUMBER OF COALITIONS AND MEMBER ORGANIZATIONS, INCLUDING ALLIANCE FOR A STRONGER FDA, ALLIANCE FOR CHILDHOOD CANCER, ALLIANCE FOR FAIR HEALTHCARE PRICING, CANCER LEADERSHIP COUNCIL, DEFENSE HEALTH RESEARCH CONSORTIUM, MAPRX COALITION, NCSL FOUNDATION FOR STATE LEGISLATURES, ONE VOICE AGAINST CANCER, PARTNERSHIP TO PROTECT COVERAGE, PATIENT QUALITY OF LIFE COALITION, PUBLIC AFFAIRS COUNCIL, AND STATE ACCESS TO INNOVATIVE MEDICINES COALITION. EMPLOYEES IN THE LLS OFFICE OF PUBLIC POLICY WORK TO ADVANCE THE ORGANIZATIONS PUBLIC POLICY PRIORITIES, DOING SO WITH SUPPORT FROM LOBBYING FIRMS AND ADVISERS RETAINED BY LLS AND IN PARTNERSHIP WITH VOLUNTEER ADVOCATES. LLS VOLUNTEER ADVOCATES ENGAGE THEIR LAWMAKERS BY CONDUCTING LETTER-WRITING CAMPAIGNS, SHARING THEIR PERSONAL STORIES, AND CONDUCTING ONE-ON-ONE VISITS IN STATE CAPITOLS AND IN WASHINGTON, D.C. - ALL WITH SUPPORT FROM THE LLS OFFICE OF PUBLIC POLICY. 0 7288293 30000 713739 291598 10043 7730391 7381460 1129903 -913685 295324 14061 7288293 5902791 1650 1726314 236177 13118 7381460 6168319 -8812 246718 9998 5902791 6192807 292934 304999 12423 6168319 0.51890 0.48110 0 0 1271123 1025988 245135 28030516 15024467 13006049 51546 51546 0 13251184 CAPITAL LEASE LIABILITY 14425281 14425281 X 392656001 -3932711 7480829 10986229 14534347 378121654 216836 216836 378338490 405655269 7480829 12318307 19799136 385856133 216835 216835 386072968 PART III, LINE 1A: THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. PART V, LINE 4: LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. PART X, LINE 2: LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2023 AND JUNE 30, 2022. PART XI, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA REVENUE 10,986,229. PART XII, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA EXPENSE 12,318,307. 1 NORTH AMERICA 1 RESEARCH FUNDING RESEARCH GRANTS 2674920 EUROPE RESEARCH FUNDING RESEARCH GRANTS 3372708 CENTRAL AMERICA & CARIBBEAN INVESTMENTS INVESTMENTS 8145536 MIDDLE EAST & NORTH AFRICA RESEARCH FUNDING RESEARCH GRANTS 30000 EAST ASIA & THE PACIFIC RESEARCH FUNDING RESEARCH GRANTS 1995135 EUROPE INVESTMENTS INVESTMENTS 8036661 1 0 0 0 1 0 24254960 0 24254960 EAST ASIA & THE PACIFIC RESEARCH GRANTS 71500 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 199160 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 100000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249500 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249975 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 1999920 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 750000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL MIDDLE EAST & NORTH AFRICA RESEARCH GRANTS 30000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 200000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 249977 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 200000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 200000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 196675 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 176051 WIRE PAYMENT 0 ACCRUAL EUROPE THERAPY ACCELERATION 250000 WIRE PAYMENT 0 ACCRUAL 0 23 1 0 1 1 0 0 PART III ACCOUNTING METHOD: PART I, LINE 2 - PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. X X X X X X X 1 THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAIL 0 0 635156 -635156 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MAIL 0 0 4897034 -4897034 5532190 -5532190 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC PR DC STUDENT VISIONARIES OF THE YEAR 2995531 2774054 221477 7999 33900 179474 1000 2775 LAKE TAHOE BIKE RIDE 3004444 2778745 225699 68781 90963 70142 5773 151299 328 155788223 139271281 16516942 2346306 14422019 2848879 831323 1793690 161788198 144824080 16964118 2423086 14546882 3098495 838096 1947764 22854323 -5890205 33230 5575 1 0.80000 33230 5575 5575 27655 OH KY 1 0 0 0 1.00000 0.00000 GORDON MILLER JR 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 0 NA SEE DESCRIPTION OF SERVICES THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC REGIONAL STAFF. 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) LLS USED RESOURCE ONE AND THOMPSON HABIB, & DENISON FOR IT'S NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR. 1 BAYLOR COLLEGE OF MEDICINE P O BOX 301207 DALLAS TX 75303 741613878 501(C)(3) 178642 0 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 241667 0 ACCRUAL RESEARCH GRANT BE THE MATCH FOUNDATION 500 N 5TH STREET MINNEAPOLIS MN 55401 411704340 501(C)(3) 50000 0 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 02241 042774441 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT BRIGHAM AND WOMENS HOSPITAL PO BOX 3149 BOSTON MA 02241 042312909 501(C)(3) 124254 0 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE ML 4900 CINCINATTI OH 45229 310833936 501(C)(3) 370000 0 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 501(C)(3) 200000 0 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 5366350 0 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 31193 582137993 501(C)(3) 1600000 0 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE PO BOX 742801 ATLANTA GA 30374 593238634 501(C)(3) 63137 0 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 3500 NEW YORK NY 10029 136171197 501(C)(3) 499527 0 ACCRUAL RESEARCH GRANT INTERNATIONAL WALDENSTROM'S MACROGLOBULINEMIA FOUNDATION 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 501(C)(3) 100000 0 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 501(C)(3) 3448600 0 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 1125000 0 ACCRUAL RESEARCH GRANT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 501(C)(3) 450000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 AB BIRMINGHAM AL 35294 636005396 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 55486 416011702 501(C)(3) 275000 0 ACCRUAL RESEARCH GRANT MYELOPROLIFERATIVE NEOPLASMS RESEARCH FOUNDATION 180 N MICHIGAN AVENUE CAROL STREAM IL 60601 364330967 501(C)(3) 100000 0 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY 633 CLARK - ROOM G547 EVANSTON IL 60208 362167817 501(C)(3) 231556 0 ACCRUAL RESEARCH GRANT OSU FOUNDATION 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 501(C)(3) 466168 0 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BLDG P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 867797 0 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIGAN BOX 223131 PITTSBURGH PA 15251 386006309 501(C)(3) 450000 0 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 2583239 0 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPITAL PO BOX 1000 DEPT 949 MEMPHIS TN 38148 620646012 501(C)(3) 460213 0 ACCRUAL RESEARCH GRANT TEMPLE UNIVERSITY PO BOX 824242 PHILADELPHIA PA 19182 231365971 501(C)(3) 200000 0 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADELPHIA PO BOX 8500 PHILADELPHIA PA 19178 231352166 501(C)(3) 245000 0 ACCRUAL RESEARCH GRANT THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)(3) 130000 0 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 501(C)(3) 622798 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 92093 956006144 501(C)(3) 370000 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 LOS ANGELES CA 90074 946036493 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK COLUMBIA UNIVE 535 W 116TH ST NEW YORK NY 10087 135598093 501(C)(3) 1185000 0 ACCRUAL RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA MEDICAL CENTER 3451 WALNUT STREET FRANKLIN BLDG P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 1574600 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 501(C)(3) 625799 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL PO BOX 402420 ATLANTA GA 30384 566001393 501(C)(3) 200000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 4266 HOUSTON TX 77210 746001118 501(C)(3) 2752751 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER PO BOX 841753 DALLAS TX 75284 756002868 501(C)(3) 309389 0 ACCRUAL RESEARCH GRANT TUFTS MEDICAL CENTER 800 WASHINGTON STREET 453 BOSTON MA 02111 042103634 501(C)(3) 49952 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS PO BOX 6508 AURORA CO 80045 846000555 501(C)(3) 1496800 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL GAINESVILLE FL 32611 596002052 501(C)(3) 1811430 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 30384 590624458 501(C)(3) 2000000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 669 WEST 34TH STREET LOS ANGELES CA 90089 951642394 501(C)(3) 174560 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 237173411 501(C)(3) 749997 0 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 522000820 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTER PO BOX 121236 DALLAS TX 75312 620476822 501(C)(3) 275473 0 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 2010236 0 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06520 060646973 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT RUTGERS UNIVERSITY 3 RUTGERS PLAZA NEW BRUNSWICK NJ 08901 226001086 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT INSTITUTE FOR CANCER RESEARCH DBA THE RESEARCH INSTITUTE OF FOX CHASE CAN 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT RHODE ISLAND HOSPITAL 593 EDDY STREET ALDRICH 3-317 PROVIDENCE RI 02903 050258954 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT MEDICAL COLLEGE OF WISCONSIN 8701 W WATERTOWN PLANK RD MILWAUKEE WI 53226 390806261 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE-NORD HALL SUITE 615 CLEVELAND OH 44106 341018992 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 98109 237156071 501(C)(3) 1472150 0 ACCRUAL RESEARCH GRANT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 450 JANE STANFORD WAY SAN FRANCISCO CA 94144 941156365 501(C)(3) 2243009 0 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 501(C)(3) 644743 0 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY CANCER INSTITUTE 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 237083114 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT DUKE UNIVERSITY MEDICAL CENTER PO BOX 602651 CHARLOTTE NC 28260 560532129 501(C)(3) 124587 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA DEPARTMENT OF MEDICINE 3451 WALNUT STREET FRANKLIN BLDG P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 854211 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF WASHINGTON 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MINNESOTA PO BOX 1450 MINNEAPOLIS MN 55485 416007513 501(C)(3) 749899 0 ACCRUAL RESEARCH GRANT BOSTON UNIVERSITY 85 EAST NEWTON ST BOSTON MA 02118 042103547 501(C)(3) 140101 0 ACCRUAL RESEARCH GRANT MONTEFIORE MEDICAL CENTER 111 EAST 210TH STREET BRONX NY 10467 131740114 501(C)(3) 100000 0 ACCRUAL RESEARCH GRANT UNC LINEBERGER COMPREHENSIVE CANCER CENTER 104 AIRPORT DRIVE CHAPEL HILL NC 27599 566001393 501(C)(3) 70000 0 ACCRUAL RESEARCH GRANT NYU GROSSMAN SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)(3) 73600 0 ACCRUAL RESEARCH GRANT CALIFORNIA UNIVERSITY OF SCIENCE AND MEDICINE 1501 VIOLET ST COLTON CA 92324 464141445 501(C)(3) 96000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS AT AUSTIN 101 E 27TH ST AUSTIN TX 78712 746000203 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT HOUSTON METHODIST RESEARCH INSTITUTE 6670 BERTNER AVENUE HOUSTON TX 77030 870721923 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT INSTITUTE OF BIOSCIENCES & TECHNOLOGY A & M UNIVERSITY SYSTEM HEALTH SCIEN 400 HARVEY MITCHELL PARKWAY SOUTH HOUSTON TX 77845 742907553 501(C)(3) 187500 0 ACCRUAL RESEARCH GRANT NORTH CAROLINA INSTITUTE FOR MEDICAL RESEARCH 411 WEST CHAPEL HILL STREET DURHAM NC 27701 561655431 501(C)(3) 75000 0 ACCRUAL RESEARCH GRANT CERV FOUNDATION 3200 VINE STREET CINCINATTI OH 45220 311347969 501(C)(3) 75000 0 ACCRUAL RESEARCH GRANT VETERAN AFFAIRS SAN DIEGO HEALTH CARE 3350 LA JOLLA VILLAGE DRIVE SAN DIEGO CA 92161 237262137 501(C)(3) 75000 0 ACCRUAL RESEARCH GRANT ECD GLOBAL ALLIANCE PO BOX 775 DERIDDER LA 70634 270759192 501(C)(3) 50000 0 ACCRUAL RESEARCH GRANT IMMUNE -ONC THERAPEUTICS INC 2431 ALOMA AVE WINTER PARK FL 32792 593226705 501(C)(3) 999999 0 FMV THERAPY ACCELERATION DREN BIO 384 FOSTER CITY BLVD FOSTER CITY CA 94404 841826535 501(C)(3) 499997 0 FMV THERAPY ACCELERATION RGENTA 300 TRADECENTER DR WOBURN MA 01801 825268874 501(C)(3) 499999 0 FMV THERAPY ACCELERATION 73 3 COPAY ASSISTANCE CLL 6363 37023234 COPAY ASSISTANCE LYMPHOMA 2994 7912796 COPAY ASSISTANCE MDS 1654 1663534 COPAY ASSISTANCE MYELOMA 7677 23312890 COPAY ASSISTANCE AML 2741 7392321 COPAY ASSISTANCE CML 72 144000 PATIENT TRAVEL ASSISTANCE 8609 4530783 PATIENT AID 48701 12722082 PART I, LINE 2: FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND OF HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTEN TIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X 0 0 0 0 0 0 0 1 0 LOUIS JDEGENNARO-END 63023 PRESIDENT & CEO 669397 0 191204 0 18945 0 19215 0 32648 0 931409 0 0 0 GWEN NICHOLS EVP, CHIEF MEDICAL OFFICER 429866 0 89255 0 33454 0 13546 0 34591 0 600712 0 0 0 TROY DUNMIRE EVP, CHIEF OPERATING OFFICER 442932 0 93424 0 1521 0 10675 0 43099 0 591651 0 0 0 DALE NISSENBAUM EVP, GENERAL COUNSEL 423691 0 76937 0 3790 0 10675 0 28759 0 543852 0 0 0 GORDON MILLER JR EVP, CHIEF FINANCIAL OFFICER 371573 0 75838 0 1942 0 15250 0 39878 0 504481 0 0 0 SUSAN BROWN SVP, CHIEF DEI OFFICER 361415 0 60596 0 3495 0 15250 0 30679 0 471435 0 0 0 COKER POWELL SVP, CHIEF DEVELOPMENT OFFICER 354360 0 64410 0 21373 0 10675 0 14845 0 465663 0 0 0 VANESSA WHITE SVP, CHIEF ADVANCEMENT OFFICER 371393 0 58678 0 1263 0 10675 0 19631 0 461640 0 0 0 LEE GREENBERGER SVP, CHIEF SCIENTIFIC OFFICER 334490 0 56963 0 9689 0 10675 0 32656 0 444473 0 0 0 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFFICER 324221 0 54452 0 3130 0 15250 0 26846 0 423899 0 0 0 PART I, LINE 7 LLS AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEE PERFORMANCE AND ORGANIZATION TARGETS. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2,PART II, COL (B) (II). X 131 2270593 FAIR MARKET VALUE X 10 70337 FAIR MARKET VALUE X VARIOUS OTHER 11 61087 FAIR MARKET VALUE X PRINTED ITEMS 3 8684 FAIR MARKET VALUE 0 0 1 0 SCHEDULE M - SUPPLEMENTAL INFORMATION PART I, COLUMN B LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SENIOR VICE PRESIDENT OF FINANCE, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE TALENT AND COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN JUNE 2023, THE TALENT AND COMPENSATION COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. IN 2023, THE TALENT AND COMPENSATION COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. FORM 990, PART VI, SECTION C, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. FORM 990, PART VII THE LEUKEMIA & LYMPHOMA SOCIETY IS PROUD TO ANNOUNCE E. ANDERS KOLB, M.D., AS ITS NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER (CEO). HE JOINED LLS ON MAY 1, 2023, SUCCEEDING LOUIS J. DEGENNARO, PH.D., WHO LED THE ORGANIZATION SINCE 2014 AND RETIRES ON JUNE 30, 2023. DR. KOLB MOST RECENTLY SERVED AS CHIEF OF THE DIVISION OF HEMATOLOGY AND ONCOLOGY OF NEMOURS CHILDREN'S HEALTH, DELAWARE VALLEY, DIRECTOR OF THE MOSELEY FOUNDATION INSTITUTE FOR CANCER AND BLOOD DISORDERS, AND VICE CHAIRMAN FOR RESEARCH IN THE DEPARTMENT OF PEDIATRICS AT THE SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY. HE JOINED NEMOURS IN 2007 AND PREVIOUSLY SERVED AS PROGRAM DIRECTOR OF BLOOD AND BONE MARROW TRANSPLANTATION. OVER HIS TENURE, MOSELEY FOUNDATION INSTITUTE HAS GROWN FROM A COMMUNITY-BASED HEMATOLOGY AND ONCOLOGY DIVISION TO A NATIONALLY RECOGNIZED AND FEDERALLY FUNDED MULTI-SITE PEDIATRIC CENTER FOR TREATMENT OF CANCER AND BLOOD DISORDERS. THE CANCER AND BLOOD DISORDER PROGRAMS IN WILMINGTON AND JACKSONVILLE NOW ROUTINELY RANK AMONG THE TOP PEDIATRIC CANCER PROGRAMS BY US NEWS AND WORLD REPORT. NEMOURS CHILDREN'S SAW A 60-FOLD INCREASE IN FEDERAL FUNDING, A 10-FOLD INCREASE IN CLINICAL TRIAL REVENUE, AND A 40-FOLD INCREASE IN PHILANTHROPY FOR CANCER AND BLOOD DISORDERS, INCLUDING A PIVOTAL COMMITMENT FROM THE MOSELEY FOUNDATION OF A MOMENTOUS $78 MILLION GIFT. DR. KOLB WILL REMAIN FACULTY EMERITUS AT NEMOURS WITH SOME LIMITED PATIENT CARE RESPONSIBILITIES. DR. KOLB ALSO SERVED AS CO-CHAIR AND MEMBER OF THE EXECUTIVE COMMITTEE OF LLS PEDAL, THE FIRST GLOBAL MASTER CLINICAL TRIAL FOR PEDIATRIC ACUTE LEUKEMIA PATIENTS. COMPENSATION IS BASED ON THE ORGANIZATION'S CALENDAR YEAR ENDED DECEMBER 31, 2022. BECAUSE PRESIDENT AND CEO E. ANDERS KOLB, M.D. JOINED LLS IN 2023, THE FISCAL YEAR 2023 FORM 990 WILL REPORT ZERO COMPENSATION FOR THE PRESIDENT. FORM 990, PART XI, LINE 9: FOREIGN CURRENCY ADJUSTMENTS -215,313. BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 4544896 -1597319 LLS LLS PEDAL INITIATIVE LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 7456139 1143657 LLS LLS TAP MIRAGEN LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP X4 LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 391498 9499750 LLS LLS TAP CONSTELLATION LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP KDAC LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS THE LLS RESEARCH PROGRAMS INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133470494 PART VII DE 501(C)(3) LINE 12A, I LLS INC 1 THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133709252 PART VII DE 501(C)(3) LINE 12A, I LLS INC 1 THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 SCHEDULE R - ADDITIONAL INFORMATION THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.